500124.IN
Dr. Reddy's Laboratories Ltd.
Healthcare · Drug Manufacturers - Specialty & Generic · IN
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
—
Market Cap
—
MomentumView details →
1D Return
—
YTD Return
—
RSI (14)
—
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
—
Market Cap
—
RSI (14)
—
MomentumView details →
1D Return
—
YTD Return
—
SummaryUpdated Jun 1, 2026
Dr. Reddy's Laboratories Limited (NYSE:RDY) is an Indian multinational pharmaceutical company founded in 1984 and headquartered in Hyderabad, India. The company has evolved from a small startup into one of India's largest pharmaceutical companies, going public on the New York Stock Exchange in 2001. Dr. Reddy's operates as an integrated pharmaceutical company with a global presence, manufacturing and marketing generic drugs, active pharmaceutical ingredients, and developing proprietary products across multiple therapeutic areas including cardiovascular, gastrointestinal, oncology, and diabetes treatments.
Latest newsMore news →
Aspen Pharmacare is pursuing the market for generic semaglutide, having obtained regulatory approval in Canada and awaiting registration in about 20 countries including Brazil and South Africa.7d agoDr. Reddy's Laboratories launched Sugammadex Injection 200 mg/2 mL and 500 mg/5 mL single-dose vials, a generic equivalent of Bridion, in the United States.36d ago